ICH E6 is the international Good Clinical Practice guideline: the standard for designing, running, recording and reporting clinical trials. Its third revision, E6 (R3), keeps the same purpose, protecting participants and producing reliable results, but changes how sponsors and sites are expected to reach it.
Quality is designed in, not inspected in
R3 asks the sponsor to decide, while the study is being designed, which factors are critical to the safety of participants and the reliability of the results. The protocol, the procedures and the data collection are then built to protect those factors.
In practice, this means simpler protocols, fewer data points collected without a reason, and a study that sites can actually deliver.
Effort follows risk
The guideline expects a risk-based and proportionate approach. Monitoring, for example, is planned around the risks of the study, combining on-site visits with central review of the data, and not applied in the same way to every site and every data point.
Sponsors keep responsibility for the study even when they hand activities to a CRO or another service provider, so oversight of those providers has to be planned and documented.
Data and systems
R3 gives more attention to how data is governed across its whole life: how it is captured, checked, corrected, transferred and kept. Computerised systems such as electronic data capture must be fit for their purpose, and access to them must be controlled and recorded.
What to do now
Review your procedures and templates against R3, train your study teams, and bring risk assessment into the design of your next protocol. If you work with a CRO, ask how its monitoring plans, data management and quality system reflect the new revision.
At Insight CRO, our clinical procedures follow ICH E6 (R3), and we train our team every time the guidelines change.
